Enhancing the efficacy of ulcerative colitis treatment by inhibiting LCN2-mediated pyroptosis through traditional processing techniques: With the rhizome of Atractylodes macrocephala Koidz. as an example.
This study suggests a traditional processing method may change a common herbal used for UC so it works better in mouse and cell models, and it proposes a specific molecular pathway (LCN2‑mediated pyroptosis) that could be targeted by a compound in the herb.
For people interested in new treatment ideas or research directions, it points to a biologically plausible mechanism worth further study.
Researchers studying IBD mechanisms or drug discovery, clinicians following experimental therapies and ethnopharmacology, and patients interested in preclinical research on herbal agents (not clinical treatment guidance).
What To Know
What to Know This paper compared raw Atractylodes macrocephala rhizome (AMR) with a rice-washed–processed form (R‑AMR) in a DSS mouse model of ulcerative colitis and in cell experiments. Both forms reduced disease activity, inflammation, and helped restore tight junction proteins; R‑AMR showed stronger effects.
The authors used bioinformatics, machine learning, and molecular docking to nominate Lipocalin‑2 (LCN2) and TIMP1 as targets and identified atractylenolide I (Atr I) as a likely active component binding LCN2.
In cell (LPS‑treated NCM460) and mouse experiments the study links therapeutic effects to inhibition of an LCN2 → NLRP3 → caspase‑1 → GSDMD pyroptosis pathway, with reduced IL‑1β/IL‑18/TNF‑α/IL‑6 and improved tight junction markers (ZO‑1, claudin‑1, MUC2). Knockdown of LCN2 lowered inflammasome activation and pyroptosis markers in vitro.
The work supports a mechanistic hypothesis that processing (rice‑washed water) alters AMR chemistry to increase Atr I activity against LCN2. The report is presented as an abstract/summary of experiments in mice and cells rather than a clinical trial. It does not provide human data or clinical dosing guidance, so it should not be taken as treatment advice.
Structured content depth: abstract. These are preclinical (mouse and cell) experiments summarized in the journal abstract; the findings have not been validated in humans. Bioinformatics and molecular docking support target selection but do not replace functional proof in patients. The study reports mechanistic and efficacy data in experimental models only.
